United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix labs ltd - hydrocortisone; neomycin sulfate; polymyxin b sulfate - ear drops - 10mg/1ml ; 3400unit/1ml ; 10000unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - hydrocortisone; neomycin sulfate; polymyxin b sulfate - ear drops - 10mg/1ml ; 3400unit/1ml ; 10000unit/1ml

Malta - English - Medicines Authority

cherubino limited - polymyxin b, sulfate, neomycin sulfate, hydrocortisone - ear drops, suspension - polymyxin b sulfate 10,000 unit(s)/millilitre ; neomycin sulfate 3,400 unit(s)/millilitre ; hydrocortisone 1 percent weight/volume - otologicals

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxosmithkline (gsk) - hydrocortisone, neomycin sulfate, polymyxin b sulfate - ear drops

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline south africa (pty) ltd - polymixin b sulphate, neomycin sulphate , hydrocortisone - ear drops - each ml contains polymixin b sulphate 10,000 iu, neomycin sulphate 3,400 iu, hydrocortisone 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - neomycin sulfate hydrocortisone - ear drops suspension - 10 millilitre

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - hydrocortisone, polymyxin b sulfate - ear drops

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - hydrocortisone 10 mg/ml, neomycin 3400 iu, polymyxin b 10000 iu - 10 mg/ml, 3400 iu, 10000 iu

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroids. cyclosporine capsules usp modified are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. cyclosporine capsules usp modified are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated. while rebound rarely occurs, most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment. cyclosporine capsules usp modified are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified. psoriasis patients who are treated with cyclosporine capsules usp modified should not receive concomitant puva or uvb therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified.